Literature DB >> 6436886

Phenylethylamine-induced stereotypies in the rat: a behavioral test system for assessment of MAO-B inhibitors.

R Ortmann, M Schaub, A Felner, J Lauber, P Christen, P C Waldmeier.   

Abstract

Stereotyped sniffing behavior together with forepaw padding--defined as the beta-phenylethylamine (PEA) syndrome--is induced by MAO-B inhibitors in rats injected with 30 mg/kg IP PEA. The comparison of the abilities of the MAO-B inhibitors to induce the syndrome and to inhibit MAO-B in rat brain homogenates indicated that at least 75% of MAO-B activity in rat brain had to be inhibited to induce the PEA syndrome. A good correlation was found between the abilities of MAO-B inhibitors to induce the behavioral syndrome and to increase levels of PEA in rat brain. Specific MAO-A inhibitors potentiated the behavioral effect of the MAO-B inhibitor deprenyl, while they did not induce the syndrome themselves or only at very high doses. Inhibitors of the reuptake of 5-HT or noradrenaline were inactive under the described experimental conditions. This behavioral test system seems to be a useful in vivo screening test in rats for detecting compounds with strong MAO-B inhibiting activity.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6436886     DOI: 10.1007/bf00432018

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  16 in total

1.  A SENSITIVE AND SPECIFIC ASSAY FOR THE ESTIMATION OF MONOAMINE OXIDASE.

Authors:  R J WURTMAN; J AXELROD
Journal:  Biochem Pharmacol       Date:  1963-12       Impact factor: 5.858

2.  Inhibition of phenylethylamine metabolism in vivo-Effect of antidepressants.

Authors:  P F Von Voigtlander; E G Losey
Journal:  Biochem Pharmacol       Date:  1976-01-15       Impact factor: 5.858

3.  Dose-response effects of beta-phenylethylamine on stereotyped behavior in pargyline-pretreated rats.

Authors:  E A Moja; D M Stoff; J C Gillin; R J Wyatt
Journal:  Biol Psychiatry       Date:  1976-12       Impact factor: 13.382

Review 4.  An animal behavior model for studying central serotonergic synapses.

Authors:  B L Jacobs
Journal:  Life Sci       Date:  1976-09-15       Impact factor: 5.037

5.  Characterization of a new, short-acting and specific inhibitor of type A monoamine oxidase.

Authors:  P C Waldmeier; P A Baumann; A Delini-Stula; R Bernasconi; K Sigg; O Buech; A E Felner
Journal:  Mod Probl Pharmacopsychiatry       Date:  1983

6.  Serotonergic properties of beta-phenethylamine in rats.

Authors:  R S Sloviter; J D Connor; E G Drust
Journal:  Neuropharmacology       Date:  1980-11       Impact factor: 5.250

7.  Enhanced selectivity of pargyline as an inhibitor of type B monoamine oxidase in harmaline-treated rats.

Authors:  R W Fuller; S K Hemrick
Journal:  Life Sci       Date:  1978-03       Impact factor: 5.037

8.  The monoamine oxidase B inhibitor deprenyl potentiates phenylethylamine behaviour in rats without inhibition of catecholamine metabolite formation.

Authors:  C Braestrup; H Andersen; A Randrup
Journal:  Eur J Pharmacol       Date:  1975-11       Impact factor: 4.432

9.  A pharmacological analysis of the hyperactivity syndrome induced by beta-phenylethylamine in the mouse.

Authors:  C T Dourish
Journal:  Br J Pharmacol       Date:  1982-09       Impact factor: 8.739

10.  The effects of 5-HT uptake- and MAO-inhibitors on L-5-HTP-induced excitation in rats.

Authors:  R Ortmann; P C Waldmeier; E Radeke; A Felner; A Delini-Stula
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1980-03       Impact factor: 3.000

View more
  7 in total

1.  A comparison of drug-seeking behavior maintained by D-amphetamine, L-deprenyl (selegiline), and D-deprenyl under a second-order schedule in squirrel monkeys.

Authors:  Sevil Yasar; József Gaál; Leigh V Panlilio; Zuzana Justinova; Szecsö V Molnár; Godfrey H Redhi; Charles W Schindler
Journal:  Psychopharmacology (Berl)       Date:  2005-11-15       Impact factor: 4.530

Review 2.  Brofaromine--a review of its pharmacological properties and therapeutic use.

Authors:  H P Volz; C H Gleiter; P C Waldmeier; M Struck; H J Möller
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

3.  Behavioral effects of α,α,β,β-tetradeutero-5-MeO-DMT in rats: comparison with 5-MeO-DMT administered in combination with a monoamine oxidase inhibitor.

Authors:  Adam L Halberstadt; David E Nichols; Mark A Geyer
Journal:  Psychopharmacology (Berl)       Date:  2012-01-06       Impact factor: 4.530

4.  Monoamine oxidase-B inhibition: a comparison of in vivo and ex vivo measures of reversible effects.

Authors:  S Turkish; P H Yu; A J Greenshaw
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

Review 5.  Contribution of β-phenethylamine, a component of chocolate and wine, to dopaminergic neurodegeneration: implications for the pathogenesis of Parkinson's disease.

Authors:  Anupom Borah; Rajib Paul; Muhammed Khairujjaman Mazumder; Nivedita Bhattacharjee
Journal:  Neurosci Bull       Date:  2013-04-10       Impact factor: 5.203

Review 6.  The Case for TAAR1 as a Modulator of Central Nervous System Function.

Authors:  Grazia Rutigliano; Alice Accorroni; Riccardo Zucchi
Journal:  Front Pharmacol       Date:  2018-01-10       Impact factor: 5.810

Review 7.  Foods with Potential Prooxidant and Antioxidant Effects Involved in Parkinson's Disease.

Authors:  Alejandra Guillermina Miranda-Díaz; Andrés García-Sánchez; Ernesto Germán Cardona-Muñoz
Journal:  Oxid Med Cell Longev       Date:  2020-08-03       Impact factor: 6.543

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.